Richard P. Micali
Direktor/Vorstandsmitglied bei Mercer Street Friends Center, Inc.
Profil
Mr. Richard P.
Micali is Vice President-Sales at Zogenix, Inc. He is on the Board of Directors at Mercer Street Friends Center, Inc.
Mr. Micali was previously employed as Senior VP-New Markets & Services Strategy by PDI, Inc. and General Manager by Pharmakon LLC.
He received his undergraduate degree from Bowling Green State University and an MBA from John Carroll University.
Aktive Positionen von Richard P. Micali
| Unternehmen | Position | Beginn |
|---|---|---|
| Mercer Street Friends Center, Inc. | Direktor/Vorstandsmitglied | 08.07.2009 |
Ehemalige bekannte Positionen von Richard P. Micali
| Unternehmen | Position | Ende |
|---|---|---|
| INTERPACE BIOSCIENCES, INC. | Corporate Officer/Principal | 03.02.2012 |
Schaumburg Investments LLC
 Schaumburg Investments LLC Miscellaneous Commercial ServicesCommercial Services Schaumburg Investments LLC provides medical marketing services. The company is headquartered in Schaumburg, IL. | Corporate Officer/Principal | 03.02.2012 |
| ZOGENIX, INC. | Vertrieb & Marketing | - |
Ausbildung von Richard P. Micali
| Bowling Green State University | Undergraduate Degree |
| John Carroll University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INTERPACE BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Mercer Street Friends Center, Inc. | |
Schaumburg Investments LLC
Schaumburg Investments LLC Miscellaneous Commercial ServicesCommercial Services Schaumburg Investments LLC provides medical marketing services. The company is headquartered in Schaumburg, IL. | Commercial Services |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
